• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: Astrotech Corporation (DE) filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    1/24/25 4:30:40 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $ASTC alert in real time by email
    astc20250122_8ka.htm
    Form 8-K/A date of report 01-07-25 true 0001001907 0001001907 2025-01-07 2025-01-07


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
     

    FORM 8-K/A
    (Amendment No. 1)
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934
     
    Date of report (Date of earliest event reported): January 7, 2025
     
    astc20250122_8kaimg001.jpg
     
     
    Astrotech Corporation
     
    (Exact Name of Registrant as Specified in Charter)
     

     
    Delaware
     
    001-34426
     
    91-1273737
    (State or Other Jurisdiction
    of Incorporation)
     
    (Commission
    File Number)
     
    (I.R.S. Employer
    Identification No.)
       
    2105 Donley Drive, Suite 100, Austin, Texas
     
    78758
    (Address of Principal Executive Offices)
     
    (Zip Code)
     
     
    (512) 485-9530
    Registrant’s Telephone Number, Including Area Code
     
    (Former Name or Former Address, if Changed Since Last Report)
     

     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
     
    ☐
    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
     
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
     
     
    ☐
    Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
     
     
    ☐
    Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
     
    Trading
    Symbol(s)
     
    Name of each exchange on which registered
    Common Stock, $0.001 par value per share
     
    ASTC
     
    NASDAQ Stock Market, LLC
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     


     

     
     
    EXPLANATORY NOTE
     
    As previously disclosed, on January 7, 2025, Jaime Hinojosa resigned from the positions of Astrotech Corporation (the “Company”) Chief Financial Officer, Treasurer and Secretary, effective February 14, 2025. This Amendment No. 1 to Form 8-K (this “Form 8-K/A”) amends and supplements the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on January 13, 2025 (the “Original Form 8-K”). This Form 8-K/A is being filed to disclose a new compensation and services arrangement with Mr. Hinojosa, and the appointment of and compensation and services arrangement with Ryan Polk as the interim Chief Financial Officer, Treasurer and Secretary, each effective February 14, 2025. Such appointment and compensation and services arrangements had not been determined at the time of the filing of the Original Form 8-K. All other information set forth in the Original Form 8-K is otherwise unchanged. This Form 8-K/A should be read in connection with the Original Form 8-K.
     
    Item 5.02         Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     
    Transition Agreement
     
    On January 13, 2025, the Company filed the Original 8-K disclosing the resignation of Mr. Hinojosa from the positions of the Company’s Chief Financial Officer, Treasurer and Secretary, effective February 14, 2025, and Mr. Hinojosa’s provision of transition services to the Company. In connection with such transition services, on January 21, 2025, the Company and Mr. Hinojosa entered into an independent contractor agreement (the “Transition Agreement”), effective February 15, 2025, setting forth the terms and conditions of such consulting arrangement.
     
    Pursuant to the Transition Agreement, Mr. Hinojosa will provide transition services to the Company on an as needed basis beginning on February 15, 2025 and terminating on June 30, 2025, unless extended, in exchange for cash compensation in the amount of $175/hour, payable every two weeks on an as billed basis. Either party may terminate the Transition Agreement upon ten business days’ written notice. The Transition Agreement also requires that Mr. Hinojosa comply with certain restrictive covenants, including confidentiality, non-compete and non-solicitation covenants.
     
    The foregoing description of the Transition Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Transition Agreement, a copy of which is attached hereto as Exhibit 10.1.
     
    Interim CFO Appointment and Independent Contractor Agreement
     
    On January 14, 2025, the Company appointed Ryan Polk, 56, as interim Chief Financial Officer, Treasurer and Secretary of the Company, effective as of February 14, 2025. Mr. Polk is a Corporate Financia Consultant to the Company and Managing Partner of With Finance Team LLC, which has provided corporate finance consulting services to the Company since May 2024. Mr. Polk has also served as the Chief Financial Officer of SideChannel, Inc. (OTCQB: SDCH), a cybersecurity advisory company, as a part-time employee since February 1, 2020, and is engaged in providing CEO and CFO services to other companies as a contractor through With Finance Team LLC. From January 2019 to September 2020, Mr. Polk served in Chief Executive Officer and Chief Financial Officer roles for Automated Retail Technologies, a retail kiosk developer and operator. Cellpoint Corporation, a mobile phone and parts supplier, hired Mr. Polk as Chief Financial Officer from June 2017 through October 2018. LDI, LLC, a family office investing in portfolio companies, employed Mr. Polk as Vice President, Business Unit Operations from July 2011 through May 2017. He is a graduate of Purdue University with two Bachelor of Science degrees from the Krannert School of Management. We believe Mr. Polk is qualified to serve as interim Chief Financial Officer based on his finance and leadership experience.
     
    In connection with such appointments, on January 22, 2025, the Company entered into an independent contractor agreement with Mr. Polk (the “CFO Agreement”), effective February 15, 2025. Pursuant to the CFO Agreement, Mr. Polk will receive monthly cash compensation in the amount of $21,000 in exchange for a minimum 80 hours per month, or a minimum 20 hours per week for any partial month, for such services. The CFO Agreement provides that either party may terminate the CFO Agreement upon sixty calendar days’ written notice and requires that Mr. Polk comply with certain confidentiality covenants. The Company will also enter into its standard form of indemnification agreement with Mr. Polk, the form of which was previously filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on December 19, 2024, and a copy of which is attached hereto as Exhibit 10.2.
     
    The Company and With Finance Team LLC entered into an independent contractor agreement in May 2024, pursuant to which With Finance Team LLC has received $147,000 in aggregate consulting fees from the Company for corporate finance consulting services. There are no family relationships between Mr. Polk and the Company or any of its subsidiaries that would require disclosure pursuant to Item 401(d) of Regulation S-K.
     
     

     
     
    The foregoing description of the CFO Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the CFO Agreement, a copy of which is attached hereto as Exhibit 10.3.
     
    Item 7.01 Regulation FD Disclosure.
     
    On January 24, 2025, the Company issued a press release announcing the new compensation and services arrangement with Mr. Hinojosa, and the appointment of and compensation and services arrangement with Ryan Polk as the interim Chief Financial Officer, Treasurer and Secretary, effective February 14, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K/A.
     
    The information set forth under Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing.
     
    Item 9.01 Financial Statements and Exhibits.
     
    (d) Exhibits
     
    Exhibit No.
    Description
      10.1*
    Independent Contractor Agreement by and between the Company and Jaime Hinojosa, dated January 21, 2025.
    10.2
    Form of Amended and Restated Indemnification Agreement (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 19, 2024).
    10.3*
    Independent Contractor Agreement by and between the Company and Ryan Polk, dated January 22, 2025.
     99.1
    Press Release of Astrotech Corporation, dated January 24, 2025.
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document).
     
    * Certain portions of this exhibit have been redacted pursuant to Item 601(a)(6) of Regulation S-K. The Company will provide a copy of such omitted materials to the Securities and Exchange Commission or its staff upon request.
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    Astrotech Corporation
     
           
     
    By:
    /s/ Thomas B. Pickens III
     
        Name: Thomas B. Pickens III  
        Chief Executive Officer, Chief Technology Officer and  
        Chairman of the Board  
     
     
    Date: January 24, 2025
     
     
    Get the next $ASTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ASTC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ASTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Becker James Frank bought $19,675 worth of shares (2,034 units at $9.67), increasing direct ownership by 14% to 16,121 units (SEC Form 4)

      4 - ASTROTECH Corp (0001001907) (Issuer)

      5/30/24 9:16:58 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Hinojosa Jaime bought $8,541 worth of shares (900 units at $9.49), increasing direct ownership by 13% to 7,881 units (SEC Form 4)

      4 - ASTROTECH Corp (0001001907) (Issuer)

      5/28/24 9:46:54 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Wilkinson Thomas Wiley bought $10,536 worth of shares (1,109 units at $9.50), increasing direct ownership by 6% to 20,862 units (SEC Form 4)

      4 - ASTROTECH Corp (0001001907) (Issuer)

      5/21/24 12:54:36 PM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $ASTC
    Financials

    Live finance-specific insights

    See more
    • Astrotech Announces Listing to the GSA as an Approved United States Government Vendor

      Astrotech Announces Listing to the GSA as an Approved United States Government Vendor AUSTIN, Texas, April 08, 2024 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) ("Astrotech" or the "Company") and its wholly owned subsidiary, 1st Detect Corporation (1st Detect), announce that 1st Detect's TRACER 1000TM is now listed in the U.S. General Services Administration (GSA) IT Schedule 70 under Contract No. GS-35F-250GA with SRI Group LLC, Special Item Number 334290.   IT Schedule 70 is a long-term contract issued by the GSA to commercial technology vendors that allows sales to the U. S. federal government, one of the largest buyers of goods and services in the world. GSA's thoro

      4/8/24 9:00:00 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Astrotech to Showcase the Tracer 1000 Trace Detector at ISC West Conference

      AUSTIN, Texas, April 02, 2024 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) ("Astrotech" or the "Company") and its wholly owned subsidiary, 1st Detect Corporation, announces that it will be showcasing its TRACER 1000 Narcotics Trace Detector ("NTD") and Explosives Trace Detector ("ETD") at the International Security Conference and Exposition, also known as ISC West, in Las Vegas, Nevada, from April 9-12, 2024, in booth number 2067. The TRACER 1000 is a high-performance laboratory instrument that is powered by the Astrotech Mass Spectrometer Technology™ ("AMS Technology"). Our mass spectrometer is capable of rapid detection of trace levels of narcotic or explosive compounds in

      4/2/24 9:00:00 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Astrotech Introduces the "Gold Standard" of Mass Spectrometry into Narcotics Detection Market with its State-of-the-Art Tracer 1000

       AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) ("Astrotech" or the "Company") and its wholly owned subsidiary, 1st Detect Corporation, announces that it is currently accepting orders for the Tracer 1000 Narcotics Trace Detector (NTD). The TRACER 1000 NTD is a high-performance laboratory instrument capable of rapid detection of trace levels of narcotic compounds in seconds. Currently, the Company's Tracer 1000 Explosive Trace Detector (ETD) is now found in multiple locations in 14 countries throughout the world. The NTD provides a ruggedized platform that can be applied across various markets including airports, border security, checkpoint, cargo,

      3/25/24 9:00:00 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $ASTC
    SEC Filings

    See more
    • SEC Form 10-Q filed by Astrotech Corporation (DE)

      10-Q - ASTROTECH Corp (0001001907) (Filer)

      5/14/25 9:20:19 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Astrotech Corporation (DE) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ASTROTECH Corp (0001001907) (Filer)

      5/13/25 4:33:56 PM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Astrotech Corporation (DE) filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ASTROTECH Corp (0001001907) (Filer)

      3/10/25 8:31:49 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $ASTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Astrotech Corporation (DE)

      SC 13D - ASTROTECH Corp (0001001907) (Subject)

      6/26/23 4:00:53 PM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Astrotech Corporation (DE) (Amendment)

      SC 13G/A - ASTROTECH Corp (0001001907) (Subject)

      2/8/23 5:29:16 PM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Astrotech Corporation (DE) (Amendment)

      SC 13G/A - ASTROTECH Corp (0001001907) (Subject)

      2/8/23 4:02:50 PM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $ASTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcfarland Robert N was granted 3,000 shares, increasing direct ownership by 28% to 13,900 units (SEC Form 4)

      4 - ASTROTECH Corp (0001001907) (Issuer)

      5/16/25 11:38:34 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Stober Eric was granted 3,000 shares, increasing direct ownership by 41% to 10,331 units (SEC Form 4)

      4 - ASTROTECH Corp (0001001907) (Issuer)

      5/16/25 10:47:45 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • CEO Pickens Thomas Boone Iii was granted 50,000 shares, increasing direct ownership by 38% to 181,385 units (SEC Form 4)

      4 - ASTROTECH Corp (0001001907) (Issuer)

      5/16/25 10:46:04 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $ASTC
    Leadership Updates

    Live Leadership Updates

    See more
    • Jaime Hinojosa Resigns as Chief Financial Officer to Work in Family Business

      AUSTIN, Texas, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) ("Astrotech" or the "Company") announced the resignation of its Chief Financial Officer, Jaime Hinojosa, effective February 14, 2025.   Mr. Hinojosa will continue to serve in the CFO role until February 14, 2025, and after that time will provide transition services to the Company on a consulting basis through June 30, 2025. In connection with this development, the Company and its Board of Directors have appointed Ryan Polk to serve as interim Chief Financial Officer. "I will be moving to Houston to be closer to family and to work for our family business," said Mr. Hinojosa. "I am grateful to Tom Pickens,

      1/24/25 8:30:00 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Astrotech Reports First Quarter of Fiscal Year 2024 Financial Results

      AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) (the "Company" or "Astrotech") reported its financial results for the first quarter of fiscal year 2024, which ended September 30, 2023. Financial Highlights & Recent Developments  Astrotech's consolidated balance sheet remains strong with $39 million in cash and liquid investments, which are anticipated to support our research and development, organic growth, and potential acquisition targets.Revenue for the quarter totaled $425 thousand compared to $38 thousand in the first quarter of the prior year due primarily to ongoing fulfillment of the previously announced 17-unit order for the TRACER 1000™ expl

      11/13/23 4:30:30 PM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • LogicMark Expands its Board of Directors by Naming Carine Schneider and Tom Wilkinson as Company's Innovative Product Pipeline Continues to Grow (Updated with Additional Details)

      LOUISVILLE, Ky., Oct. 31, 2023 (GLOBE NEWSWIRE) -- LogicMark, Inc. (NASDAQ:LGMK) (the "Company"), creator of the most innovative personal safety and security technology designed for the care economy, today announced that Carine Schneider, FGE, and Tom Wilkinson will join as the newest members of its Board of Directors. Ms. Schneider and Mr. Wilkinson both bring decades of corporate governance, finance, operations, technology, M&A, advisory and CEO experience. "I am thrilled to welcome Carine and Tom to our Board of Directors. Carine's demonstrated history of leadership and innovation in the technology and finance sectors, coupled with Tom's extensive experience and influential work with a

      10/31/23 11:54:15 AM ET
      $ASTC
      $LGMK
      $SONM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Industrial Specialties
      Health Care

    $ASTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Astrotech Reports Third Quarter of Fiscal Year 2025 Financial Results

      AUSTIN, Texas, May 13, 2025 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) (the "Company" or "Astrotech") reported its financial results for the third quarter of fiscal year 2025, which ended March 31, 2025. Thomas B. Pickens, III, Astrotech's Chairman, Chief Executive Officer and Chief Technology Officer, said, "Our customizable, portable and field updatable mass spectrometry instruments have the potential to be a game changer in a growing list of large end markets such as airport security and cargo scanning, narcotics detection, environmental monitoring and chemical processing. I am very proud of our team's accomplishments, as we now have launched four product lines that we bel

      5/13/25 4:30:00 PM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 1st Detect Unveils Enhanced TRACER 1000 Narcotics Trace Detector Intended to Combat Synthetic Opiates and Novel Psychoactive Substances

      AUSTIN, Texas, March 10, 2025 (GLOBE NEWSWIRE) --  Astrotech Corporation (NASDAQ:ASTC) today announced the launch of its enhanced TRACER 1000™ Narcotics Trace Detector ("TRACER 1000 NTD") from its 1st Detect subsidiary. This innovative mobilized mass spectrometer is specifically configured to screen for the full range of synthetic opiates and novel psychoactive substances ("NPS"), delivering accuracy and speed to counter the global drug crisis. Improving Drug Detection with Advanced Mass Spectrometry The latest iteration of the TRACER 1000 NTD represents a significant leap forward in portable trace detection. Unlike conventional methods, the TRACER 1000 NTD leverages cutting-edge mass sp

      3/10/25 8:30:00 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Astrotech Creates New Subsidiary EN-SCAN, Inc.

      AUSTIN, Texas, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) announced today that it has created a new wholly owned subsidiary, EN-SCAN, Inc. ("EN-SCAN"), to manufacture and sell a new line of instruments built for environmental testing applications using its proprietary ATi Gas Chromatograph ("GC") and Astrotech Mass Spectrometer Technology™ ("MS"). The EN-SCAN product line has been designed for outdoor field work that can be used on-site for real-time air, water, and soil analysis providing instant feedback for accurate contamination source location and migration. "EN-SCAN has been developed to fill a gap in the environmental testing market needing a durable and

      2/28/25 8:30:00 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials